Molecular Imaging Diagnosis of Renal Cancer Using <sup>99m</sup>Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques
Novel molecular imaging opportunities to preoperatively diagnose renal cell carcinoma is under development and will add more value in limiting the postoperative renal function loss and morbidity. We aimed to comprehensively review the research on single photon emission computed tomography/computed t...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/4/593 |
| _version_ | 1797621520585981952 |
|---|---|
| author | Octavian Sabin Tataru Michele Marchioni Felice Crocetto Biagio Barone Giuseppe Lucarelli Francesco Del Giudice Gian Maria Busetto Alessandro Veccia Arturo Lo Giudice Giorgio Ivan Russo Stefano Luzzago Mattia Luca Piccinelli Mihai Dorin Vartolomei Gennaro Musi Matteo Ferro |
| author_facet | Octavian Sabin Tataru Michele Marchioni Felice Crocetto Biagio Barone Giuseppe Lucarelli Francesco Del Giudice Gian Maria Busetto Alessandro Veccia Arturo Lo Giudice Giorgio Ivan Russo Stefano Luzzago Mattia Luca Piccinelli Mihai Dorin Vartolomei Gennaro Musi Matteo Ferro |
| author_sort | Octavian Sabin Tataru |
| collection | DOAJ |
| description | Novel molecular imaging opportunities to preoperatively diagnose renal cell carcinoma is under development and will add more value in limiting the postoperative renal function loss and morbidity. We aimed to comprehensively review the research on single photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography computed tomography (PET-CT) molecular imaging and to enhance the urologists’ and radiologists’ knowledge of the current research pattern. We identified an increase in prospective and also retrospective studies that researched to distinguish between benign and malignant lesions and between different clear cell renal cell carcinoma subtypes, with small numbers of patients studied, nonetheless with excellent results on specificity, sensitivity and accuracy, especially for <sup>99m</sup>Tc-sestamibi SPECT/CT that delivers quick results compared to a long acquisition time for girentuximab PET-CT, which instead gives better image quality. Nuclear medicine has helped clinicians in evaluating primary and secondary lesions, and has lately returned with new and exciting insights with novel radiotracers to reinforce its diagnostic potential in renal carcinoma. To further limit the renal function loss and post-surgery morbidity, future research is mandatory to validate the results and to clinically implement the diagnostic techniques in the context of precision medicine. |
| first_indexed | 2024-03-11T08:57:10Z |
| format | Article |
| id | doaj.art-a0deb1b8853045ad8c8ce606083946f9 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T08:57:10Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-a0deb1b8853045ad8c8ce606083946f92023-11-16T20:00:07ZengMDPI AGDiagnostics2075-44182023-02-0113459310.3390/diagnostics13040593Molecular Imaging Diagnosis of Renal Cancer Using <sup>99m</sup>Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel TechniquesOctavian Sabin Tataru0Michele Marchioni1Felice Crocetto2Biagio Barone3Giuseppe Lucarelli4Francesco Del Giudice5Gian Maria Busetto6Alessandro Veccia7Arturo Lo Giudice8Giorgio Ivan Russo9Stefano Luzzago10Mattia Luca Piccinelli11Mihai Dorin Vartolomei12Gennaro Musi13Matteo Ferro14Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, RomaniaDepartment of Medical, Oral and Biotechnological Sciences, G. d’Annunzio, University of Chieti, 66100 Chieti, ItalyDepartment of Neurosciences and Reproductive Sciences and Odontostomatology, University of Naples “Federico II”, 80131 Naples, ItalyDepartment of Neurosciences and Reproductive Sciences and Odontostomatology, University of Naples “Federico II”, 80131 Naples, ItalyDepartment of Precision and Regenerative Medicine and Ionian Area, Urology, Andrology and Kidney Transplantation Unit, University of Bari, 70124 Bari, ItalyDepartment of Maternal Infant and Urologic Sciences, “Sapienza” University of Rome, Policlinico Umberto I Hospital, 00161 Rome, ItalyDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, ItalyUrology Unit, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, ItalyDepartment of Urology, University of Catania, 95124 Catania, ItalyDepartment of Urology, University of Catania, 95124 Catania, ItalyDepartment of Urology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, ItalyDepartment of Urology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, ItalyInstitution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, RomaniaDepartment of Urology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, ItalyDepartment of Urology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, ItalyNovel molecular imaging opportunities to preoperatively diagnose renal cell carcinoma is under development and will add more value in limiting the postoperative renal function loss and morbidity. We aimed to comprehensively review the research on single photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography computed tomography (PET-CT) molecular imaging and to enhance the urologists’ and radiologists’ knowledge of the current research pattern. We identified an increase in prospective and also retrospective studies that researched to distinguish between benign and malignant lesions and between different clear cell renal cell carcinoma subtypes, with small numbers of patients studied, nonetheless with excellent results on specificity, sensitivity and accuracy, especially for <sup>99m</sup>Tc-sestamibi SPECT/CT that delivers quick results compared to a long acquisition time for girentuximab PET-CT, which instead gives better image quality. Nuclear medicine has helped clinicians in evaluating primary and secondary lesions, and has lately returned with new and exciting insights with novel radiotracers to reinforce its diagnostic potential in renal carcinoma. To further limit the renal function loss and post-surgery morbidity, future research is mandatory to validate the results and to clinically implement the diagnostic techniques in the context of precision medicine.https://www.mdpi.com/2075-4418/13/4/593<sup>99m</sup>Tc-sestamibi SPECTgirentuximab PET-CTmolecular imagingrenal cancer |
| spellingShingle | Octavian Sabin Tataru Michele Marchioni Felice Crocetto Biagio Barone Giuseppe Lucarelli Francesco Del Giudice Gian Maria Busetto Alessandro Veccia Arturo Lo Giudice Giorgio Ivan Russo Stefano Luzzago Mattia Luca Piccinelli Mihai Dorin Vartolomei Gennaro Musi Matteo Ferro Molecular Imaging Diagnosis of Renal Cancer Using <sup>99m</sup>Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques Diagnostics <sup>99m</sup>Tc-sestamibi SPECT girentuximab PET-CT molecular imaging renal cancer |
| title | Molecular Imaging Diagnosis of Renal Cancer Using <sup>99m</sup>Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques |
| title_full | Molecular Imaging Diagnosis of Renal Cancer Using <sup>99m</sup>Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques |
| title_fullStr | Molecular Imaging Diagnosis of Renal Cancer Using <sup>99m</sup>Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques |
| title_full_unstemmed | Molecular Imaging Diagnosis of Renal Cancer Using <sup>99m</sup>Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques |
| title_short | Molecular Imaging Diagnosis of Renal Cancer Using <sup>99m</sup>Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques |
| title_sort | molecular imaging diagnosis of renal cancer using sup 99m sup tc sestamibi spect ct and girentuximab pet ct current evidence and future development of novel techniques |
| topic | <sup>99m</sup>Tc-sestamibi SPECT girentuximab PET-CT molecular imaging renal cancer |
| url | https://www.mdpi.com/2075-4418/13/4/593 |
| work_keys_str_mv | AT octaviansabintataru molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT michelemarchioni molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT felicecrocetto molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT biagiobarone molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT giuseppelucarelli molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT francescodelgiudice molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT gianmariabusetto molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT alessandroveccia molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT arturologiudice molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT giorgioivanrusso molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT stefanoluzzago molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT mattialucapiccinelli molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT mihaidorinvartolomei molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT gennaromusi molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques AT matteoferro molecularimagingdiagnosisofrenalcancerusingsup99msuptcsestamibispectctandgirentuximabpetctcurrentevidenceandfuturedevelopmentofnoveltechniques |